Australia - English - Department of Health (Therapeutic Goods Administration)

bio-practica pty ltd - allium sativum, quantity: 20 mg (equivalent: allium sativum, qty 1 g); phellodendron amurense, quantity: 168.35 mg (equivalent: phellodendron amurense, qty 3.367 g); origanum oil spanish, quantity: 30 mg; punica granatum, quantity: 40 mg (equivalent: punica granatum, qty 2 g); nigella sativa, quantity: 50 mg (equivalent: nigella sativa, qty 1 g); cinnamomum cassia, quantity: 37.5 mg (equivalent: cinnamomum cassia, qty 750 mg; equivalent: coumarin, qty 0.38 microgram) - tablet, film coated - excipient ingredients: pregelatinised rice starch; colloidal anhydrous silica; rice starch; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; povidone; crospovidone; croscarmellose sodium; magnesium stearate; chlorophyllin-copper complex; carnauba wax; maltodextrin; macrogol 400; hypromellose - traditionally used in ayurvedic medicine to anala mandya hara/increase in appetite ; traditionally used in ayurvedic medicine to atisara hara/ease diarrhoea ; traditionally used in ayurvedic medicine to anaha hara/anti flatulent ; traditionally used in ayurvedic medicine to krimighna (anthelmintic)/assists to expel thread worms ; traditionally used in western herbal medicine to sudorific/diaphoretic/enhance/promote sweating/perspiration ; traditionally used in western herbal medicine to maintain/support general health and wellbeing ; traditionally used in western herbal medicine to astringent/tightens tissues ; traditionally used in ayurvedic medicine to orexigenic/improve/promote healthy appetite ; traditionally used in chinese medicine to decrease/reduce/relieve diarrhoea ; traditionally used in western herbal medicine to decrease/reduce/relieve diarrhoea ; traditionally used in ayurvedic medicine to decrease/reduce/relieve diarrhoea ; traditionally used in western herbal medicine to decrease/reduce/relieve colic (wind/gas pain) ; traditionally used in ayurvedic medicine to decrease/reduce/relieve flatulence/carminative ; traditionally used in western herbal medicine to decrease/reduce/relieve flatulence/carminative ; traditionally used in ayurvedic medicine to maintain/support healthy digestive system function ; traditionally used in chinese medicine to decrease/reduce/relieve abdominal pain/discomfort ; traditionally used in western herbal medicine to decrease/reduce/relieve abdominal spasm ; traditionally used in western herbal medicine to antiemetic/decrease/reduce/relieve vomiting ; traditionally used in western herbal medicine to decrease/reduce/relieve nausea ; traditionally used in western herbal medicine to expectorant/clear respiratory tract mucous

United States - English - NLM (National Library of Medicine)

lantheus medical imaging, inc. - gallium citrate ga-67 (unii: 4ljk511z86) (gallium cation ga-67 - unii:99t03j52w0) - gallium cation ga-67 2.0 mci in 1 ml - gallium citrate ga 67 injection may be useful in demonstrating the presence of the following malignancies: hodgkins disease, lymphomas and bronchogenic carcinoma. positive ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. gallium citrate ga 67 injection may be useful as an aid in detecting some acute inflammatory lesions. none known.

United States - English - NLM (National Library of Medicine)

curium us llc - gallium chloride ga-67 (unii: a04b19o2b0) (gallium cation ga-67 - unii:99t03j52w0) - gallium cation ga-67 2 mci in 1 ml - gallium citrate ga 67 injection may be useful to demonstrate the presence and extent of hodgkin's disease, lymphoma, and bronchogenic carcinoma. positive gallium ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. gallium citrate ga 67 injection may be useful as an aid in detecting some acute inflammatory lesions. none.

Israel - English - Ministry of Health

isorad ltd, israel - gallium (67ga) citrate; sodium citrate - solution for injection - gallium (67ga) citrate 1.5 - 2 mci; sodium citrate 1.5 - 2 mg - gallium (67ga) citrate - gallium (67ga) citrate - inflammatory lesions and abscesses. primary and metastatic tumors hodgkin's disease. lymphomas and brochogenic carcinoma.

Ireland - English - HPRA (Health Products Regulatory Authority)

curium netherlands b.v. - gallium (67 ga) citrate - solution for injection - 37 megabecquerel(s)/millilitre - other diagnostic radiopharmaceuticals for inflammation and infection detection; gallium (67ga) citrate

United States - English - NLM (National Library of Medicine)

standard homeopathic company - allium cepa whole (unii: 8p2vlg2456) (allium cepa whole - unii:8p2vlg2456) - allium cepa whole 30 [hp_x] in 1 g - runny nose,cold or hay fever

United States - English - NLM (National Library of Medicine)

ucsf radiopharmaceutical facility - gallium ga-68 gozetotide (unii: zj0ekr6m10) (gallium ga-68 gozetotide - unii:zj0ekr6m10) - gallium ga 68 gozeotide injection is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. none risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there are no available data with gallium ga 68 gozetotide injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. all radiopharmaceuticals, including gallium ga 68 gozetotide injection, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. animal reproduction studies have not been conducted with gallium ga 68 gozetotide injection. risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there ar

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - gallium (67ga) citrate, quantity: 100 mbq/ml - injection, solution - excipient ingredients: benzyl alcohol; sodium hydroxide; sodium citrate dihydrate; water for injections - (as per r46108) gallium (67ga) citrate injection bp may be useful in demonstrating the presence and extent of hodgkin's disease, lymphomas and bronchogenic carcinoma. positive intake in the absence of prior symptoms may indicate a potential disease state. new indications as specified in the letter of 18 october 1993 from dr alex proudfoot: gallium (67ga) citrate injection bp may be useful in demonstrating the presence and extent of hodgkin's disease, lymphomas and bronchogenic carcinoma. positive uptake in the absence of prior symptoms may indicate a potential disease state. gallium (67ga) may also be useful as an aid in detecting some acute inflammatory lesions. gallium (67ga) citrate injection bp may also be useful as an aid in detecting some acute inflammatory lesions. (as per r46110) gallium (67ga) citrate injection bp may be useful in demonstrating the presence and extent of hodgkin's disease, lymphomas and bronchogenic carcinoma. positive uptake in the absence of prior symptoms may indicate a potent

Canada - English - Health Canada

curium canada inc - gallium citrate ga 67 - solution - 74mbq - gallium citrate ga 67 74mbq - roentgenography

United States - English - NLM (National Library of Medicine)

ucla biomedical cyclotron - gallium ga-68 gozetotide (unii: zj0ekr6m10) (gallium ga-68 gozetotide - unii:zj0ekr6m10) - gallium ga 68 gozetotide injection is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. none risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there are no available data with gallium ga 68 gozetotide injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. all radiopharmaceuticals, including gallium ga 68 gozetotide injection, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. animal reproduction studies have not been conducted with gallium ga 68 gozetotide. risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there are no data